Navigation Links
Osteotech Receives FDA Clearance for its Next Generation Grafting Material
Date:10/29/2008

EATONTOWN, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative healing, announced today that it has received 510(k) clearance from the United States Food and Drug Administration ("FDA") for its next generation grafting material. Osteotech received 510(k) clearance for this material as a bone graft substitute, and as a bone void filler, for use in the spine, pelvis and extremities.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, stated, "Receiving FDA clearance for our next generation grafting material is a great accomplishment for our team and another key milestone in our strategic plan. During our November 7, 2008 conference call, we will provide much more insight into this grafting material, its procedural uses and the timeline for introduction."

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech, or this press release, please go to Osteotech's website at http://www.osteotech.com.

This press release may contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward- looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could affect these results are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotech Announces Third Quarter Earnings Release and Conference Call Schedule
2. Cato T. Laurencin, M.D., Ph.D. to Join Osteotech Board of Directors
3. Osteotechs Plexur M(TM) Biocomposite Receives FDA Clearance in Spine
4. Osteotechs Plexur(R) Technology to Be Used in Craniofacial Reconstruction Program Funded by the Armed Forces Institute of Regenerative Medicine
5. Osteotech Posts First Quarter Earnings Per Share of $.05 on Revenue Growth of 10%
6. Osteotechs Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine
7. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
8. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
9. U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,146
10. Osteotech to Present at the Sidoti Conference in New York
11. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of ... their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been ... Target to its list of well-respected retailers. This list includes such fine stores ...
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):